IBRX Latest Headlines

Here are the major earnings after the close Tuesday

at seekingalpha.com (Tue, 3-Mar 10:00 AM)

ImmunityBio Q4 2026 Earnings Preview

at seekingalpha.com (Mon, 2-Mar 5:38 PM)

Top 10 Healthcare Stocks of February

at seekingalpha.com (Mon, 2-Mar 3:31 PM)

ImmunityBio’s Trial: ANKTIVA Plus BCG Shows Promising Results in Bladder Cancer Study

Market Chameleon (Thu, 26-Feb 7:44 AM)

ImmunityBio’s Leadership Highlighted as Dr. Patrick Soon-Shiong Joins Renowned Cancer Experts at Milken Institute Summit

Market Chameleon (Tue, 24-Feb 11:17 AM)

ImmunityBio's ANKTIVA Gains Saudi FDA Green Light, Securing Key MENA Partnerships for Bladder and Lung Cancer Launch

Market Chameleon (Mon, 23-Feb 11:07 AM)

IBRX’s ANKTIVA Achieves 700% Revenue Growth, First Global Lung Cancer Approval, and Rapid Expansion Across 33 Countries

Market Chameleon (Mon, 23-Feb 8:12 AM)

ImmunityBio Expands ANKTIVA Access Across Europe Through New Distribution Partnership and Irish Subsidiary

Market Chameleon (Thu, 19-Feb 9:20 AM)

IBRX Faces Legal Scrutiny Amid Ongoing Clinical Trial Uncertainty—What Should Investors Watch?

Market Chameleon (Wed, 18-Feb 11:09 AM)

ImmunityBio Advances in Saudi Arabia: rBCG and ANKTIVA Expansion Brighten Middle East Prospects

Market Chameleon (Tue, 17-Feb 7:06 AM)

ImmunityBio’s Phase 2 CAR-NK Cell Therapy Trial Sets New Ground With Chemotherapy-Free Approach in Indolent Lymphomas

Market Chameleon (Mon, 2-Feb 8:18 AM)

ImmunityBio’s Chemo-Free Therapy Shows Promising Survival and Immune Recovery in Challenging Glioblastoma Cases

Market Chameleon (Fri, 23-Jan 7:28 AM)

ImmunityBio's CD19 CAR-NK Therapy Delivers 15-Month Remission in Waldenstrom Lymphoma—Chemotherapy-Free Approach Shows 100% Disease Control

Market Chameleon (Tue, 20-Jan 9:55 AM)